Enterprise Value

-14.81M

Cash

29.73M

Avg Qtr Burn

-4.204M

Short % of Float

0.38%

Insider Ownership

0.55%

Institutional Own.

6.81%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Rigosertib + Pembrolizumab Details
Melanoma, Skin cancer, Cancer

Phase 2

Data readout

Rigosertib (RAS inhibitor) Details
Cutaneous squamous cell carcinoma, Solid tumor/s, Cancer

Phase 2

Update

Rigosertib + Nivolumab Details
Non-small cell lung carcinoma, Cancer

Phase 1/2

Data readout

Narazaciclib + letrozole Details
Solid tumor/s, Cancer, Endometrial cancer

Phase 1/2

Data readout

Narazaciclib (ON 123300) (CDK4/6 & ARK5 inhibitor) Details
Solid tumor/s, Cancer, Breast cancer, ER+/HER2- breast cancer, Metastatic breast cancer

Phase 1

Data readout

Rigosertib Details
Myelodysplastic syndrome

Failed

Discontinued